News for Hanall Biopharma Co.,Ltd (009420.KS)

HanAll records revenue of 36.8 billion KRW in the third quarter, with an operating profit of 430 million KRW. Results for the Phase 1 study in healthy subjects for HL192 (ATH-399A), a novel compound targeting Parkinson's Disease, are expected in November 2024. ROCKVILLE, Md. and SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter of 2024 and provided business updates.

HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products. HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) technology, targeting ophthalmic and otic diseases. Progress in clinical development programs continued including the completion of Phase 1 study for HL192 (ATH-399A) in Parkinson's Disease, with results expected in the second half of 2024 and initiation of VELOS-4 Phase 3 study on tanfanercept for Dry Eye Disease. ROCKVILLE, Md. and SEOUL, South Korea, July 26, 2024 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the second quarter of 2024 and provided business updates.

The Global Graves’ Disease (Overactive Thyroid) Market Size was Valued at USD 390.8 Million in 2023 and the Worldwide Graves’ Disease (Overactive Thyroid)...

Tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score (CCSS) or...

Financial results for the first quarter ended with revenue of KRW 28.8 billion, up by 20 percent compared to the same period in 2022 HanAll made a strong start...

/PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines...

/PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420.KS) today announced that it is investing in Interon Laboratories, Inc., a US-based biotechnology...

Farmington, Jan. 16, 2023 (GLOBE NEWSWIRE) -- The Antihypertensive Drugs Market is estimated to reach a valuation of USD 30.2 Billion by 2022, growing at...

/PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS), a global biopharma company committed to deliver innovative and impactful therapeutics to address severe...